Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 201

1.

Structure-based virtual screening approach to the discovery of p38 MAP kinase inhibitors.

Choi H, Park HJ, Shin JC, Ko HS, Lee JK, Lee S, Park H, Hong S.

Bioorg Med Chem Lett. 2012 Mar 15;22(6):2195-9. doi: 10.1016/j.bmcl.2012.01.104. Epub 2012 Feb 2.

PMID:
22342625
2.

Structure-based virtual screening approach to the discovery of phosphoinositide 3-kinase alpha inhibitors.

Park H, Choi H, Hong S, Kim D, Oh DS, Hong S.

Bioorg Med Chem Lett. 2011 Apr 1;21(7):2021-4. doi: 10.1016/j.bmcl.2011.02.015. Epub 2011 Feb 26. Erratum in: Bioorg Med Chem Lett. 2011 Jun 15;21(12):3839.

PMID:
21354792
3.

Discovery of MEK/PI3K dual inhibitor via structure-based virtual screening.

Park H, Lee S, Hong S.

Bioorg Med Chem Lett. 2012 Aug 1;22(15):4946-50. doi: 10.1016/j.bmcl.2012.06.041. Epub 2012 Jun 21.

PMID:
22771009
4.

Identification of novel inhibitors of mitogen-activated protein kinase phosphatase-1 with structure-based virtual screening.

Park H, Jeon JY, Kim SY, Jeong DG, Ryu SE.

J Comput Aided Mol Des. 2011 May;25(5):469-75. doi: 10.1007/s10822-011-9432-2. Epub 2011 May 13.

PMID:
21567231
5.

Identification of novel BRAF kinase inhibitors with structure-based virtual screening.

Park H, Choi H, Hong S, Hong S.

Bioorg Med Chem Lett. 2011 Oct 1;21(19):5753-6. doi: 10.1016/j.bmcl.2011.08.010. Epub 2011 Aug 8.

PMID:
21873050
6.

Identification of novel inhibitors of tropomyosin-related kinase A through the structure-based virtual screening with homology-modeled protein structure.

Park H, Chi O, Kim J, Hong S.

J Chem Inf Model. 2011 Nov 28;51(11):2986-93. doi: 10.1021/ci200378s. Epub 2011 Nov 2.

PMID:
22017333
7.

Structure-based virtual screening approach to the discovery of novel PTPMT1 phosphatase inhibitors.

Park H, Kim SY, Kyung A, Yoon TS, Ryu SE, Jeong DG.

Bioorg Med Chem Lett. 2012 Jan 15;22(2):1271-5. doi: 10.1016/j.bmcl.2011.10.083. Epub 2011 Nov 3.

PMID:
22115589
8.

Discovery of potent inhibitors of receptor protein tyrosine phosphatase sigma through the structure-based virtual screening.

Park H, Chien PN, Ryu SE.

Bioorg Med Chem Lett. 2012 Oct 15;22(20):6333-7. doi: 10.1016/j.bmcl.2012.08.081. Epub 2012 Aug 29.

PMID:
22989533
9.

Virtual screening and biochemical evaluation to identify new inhibitors of mammalian target of rapamycin (mTOR).

Park H, Choe H, Hong S.

Bioorg Med Chem Lett. 2014 Feb 1;24(3):835-8. doi: 10.1016/j.bmcl.2013.12.081. Epub 2013 Dec 27.

PMID:
24393580
10.

Identification of potent VHZ phosphatase inhibitors with structure-based virtual screening.

Park H, Park SY, Oh JJ, Ryu SE.

J Biomol Screen. 2013 Feb;18(2):226-31. doi: 10.1177/1087057112463067. Epub 2012 Oct 4.

PMID:
23042075
11.

Structure-based de novo design and synthesis of aminothiazole-based p38 MAP kinase inhibitors.

Park H, Lee S, Hong S.

Bioorg Med Chem Lett. 2015 Sep 15;25(18):3784-7. doi: 10.1016/j.bmcl.2015.07.094. Epub 2015 Aug 5.

PMID:
26259807
12.
13.

Part 1: Structure-Activity Relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.

Wurz RP, Pettus LH, Xu S, Henkle B, Sherman L, Plant M, Miner K, McBride H, Wong LM, Saris CJ, Lee MR, Chmait S, Mohr C, Hsieh F, Tasker AS.

Bioorg Med Chem Lett. 2009 Aug 15;19(16):4724-8. doi: 10.1016/j.bmcl.2009.06.058. Epub 2009 Jun 17.

PMID:
19574047
14.

Homology modeling and virtual screening approaches to identify potent inhibitors of slingshot phosphatase 1.

Park H, Park SY, Ryu SE.

J Mol Graph Model. 2013 Feb;39:65-70. doi: 10.1016/j.jmgm.2012.10.008. Epub 2012 Nov 8.

PMID:
23220283
15.

Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.

Comess KM, Sun C, Abad-Zapatero C, Goedken ER, Gum RJ, Borhani DW, Argiriadi M, Groebe DR, Jia Y, Clampit JE, Haasch DL, Smith HT, Wang S, Song D, Coen ML, Cloutier TE, Tang H, Cheng X, Quinn C, Liu B, Xin Z, Liu G, Fry EH, Stoll V, Ng TI, Banach D, Marcotte D, Burns DJ, Calderwood DJ, Hajduk PJ.

ACS Chem Biol. 2011 Mar 18;6(3):234-44. doi: 10.1021/cb1002619. Epub 2011 Jan 20.

PMID:
21090814
16.

Discovery of 5-substituted-N-arylpyridazinones as inhibitors of p38 MAP kinase.

Jerome KD, Hepperle ME, Walker JK, Xing L, Devraj RV, Benson AG, Baldus JE, Selness SR.

Bioorg Med Chem Lett. 2010 May 15;20(10):3146-9. doi: 10.1016/j.bmcl.2010.03.088. Epub 2010 Mar 31.

PMID:
20395140
17.

Implications for selectivity of 3,4-diarylquinolinones as p38alphaMAP kinase inhibitors.

Peifer C, Urich R, Schattel V, Abadleh M, Röttig M, Kohlbacher O, Laufer S.

Bioorg Med Chem Lett. 2008 Feb 15;18(4):1431-5. doi: 10.1016/j.bmcl.2007.12.073. Epub 2008 Jan 5.

PMID:
18207396
18.

p38α MAPK and Type I Inhibitors: Binding Site Analysis and Use of Target Ensembles in Virtual Screening.

Astolfi A, Iraci N, Sabatini S, Barreca ML, Cecchetti V.

Molecules. 2015 Aug 31;20(9):15842-61. doi: 10.3390/molecules200915842.

19.

Identification of novel inhibitors of extracellular signal-regulated kinase 2 based on the structure-based virtual screening.

Park H, Bahn YJ, Jeong DG, Woo EJ, Kwon JS, Ryu SE.

Bioorg Med Chem Lett. 2008 Oct 15;18(20):5372-6. doi: 10.1016/j.bmcl.2008.09.058. Epub 2008 Sep 18.

PMID:
18835158
20.

3D-QSAR and molecular docking studies on fused pyrazoles as p38α mitogen-activated protein kinase inhibitors.

Lan P, Huang ZJ, Sun JR, Chen WM.

Int J Mol Sci. 2010 Sep 17;11(9):3357-74. doi: 10.3390/ijms11093357.

Supplemental Content

Support Center